Recent News from (OTC: ATNM)
| Actinium Pharmaceuticals: Neglected Assets In Niche Oncology|
|Opportunity The best opportunities for outsized gains in biotech tend to be found in companies that are left-for-dead and/or misunderstood by market participants. However, due to the market's propensity for self-reinforcing dynamics, it can be challenging for contrarian investors to catch a ...|
| Date: May, 04 2018 05:00|
| Key events next week - healthcare|
|Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more ... |
| Date: April, 06 2018 07:14|
| Blog Exposure - Actinium Announces Collaboration with Astellas Pharma|
|Stock Monitor: Auris Medical Holding Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ) ("Actinium"). If you want access to this report all you need to do is sign up n...|
|Source: ACCESSWIRE IA|
| Date: April, 02 2018 07:30|
| Key events next week - healthcare (continued #1)|
|Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR ); Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS...|
| Date: March, 16 2018 10:26|
Last 5 Days Trading Activity
Last 5 Days Short Activity
Short Analysis provided by Squeeze Report. Get a complete short report on ATNM.
About Actinium Pharmaceuticals, Inc. (OTC: ATNM)
Actinium Pharmaceuticals, Inc. ATNM.OB is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium and bismuth and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company s lead radiopharmaceutical Iomab TM B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase clinical study of Iomab B in refractory and relapsed Acute Myeloid Leukemia AML patients over the age of with a primary endpoint of durable complete remission. The company s second program, Actimab A, is continuing its clinical development in a Phase / trial for newly diagnosed AML patients over the age of in a single arm multicenter trial.
- Kaushik Dave / CEO
- Dragan Cicic / COO, Chief Med. Officer
- Corey Sohmer / VP, Fin.
- Sergio Traversa / CFO, Interim CFO
- Sergio Traversa / NonExecutive Director
- Kaushik Dave /
Current Share Structure
- Market Cap: $31,282,022 - 03/20/2018
- Authorized: 200,000,000 - 01/28/2014
- Issue and Outstanding: 80,025,639 - 11/03/2017
Recent Filings from (OTC: ATNM)
Daily Technical Chart for (OTC: ATNM)
Stay tuned for daily updates and more on (OTC: ATNM)
It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter
More to come on (OTC: ATNM)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATNM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of ATNM and does not buy, sell, or trade any shares of ATNM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/